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Objective: To employ elemental Strontium as a tracer of bone turnover, in the presence (or absence) of the
bisphosphonate drug Alendronate, in order to spatially map osteophytogenesis and other bone turnover
in rats developing post-traumatic secondary osteoarthritis (PTOA).
Methods: PTOA was induced in rats by medial meniscectomy surgery. We utilized in-vivo microfocal
computed tomography (CT) to follow bony adaptations in groups for 8 weeks after surgery, either with or
without alendronate treatment. Electron probe microanalysis (EPMA) was used to detect Strontium
incorporation in mineralizing tissues. Histologic studies were conducted on the same samples using
Safranin-O/fast green and Tetrachrome staining of decalciﬁed sections to examine articular cartilage
health and osteophyte formation at the sites of elemental Strontium deposition.
Results: EPMA revealed uniform incorporation of Strontium over actively remodeling trabecular surfaces
in normal control rats. That pattern was signiﬁcantly altered after meniscectomy surgery resulting in
greater Strontium signal at the developing osteophyte margins. Alendronate treatment inhibited
osteophyte development by 40% and 51% quantiﬁed by micro-CT volumetric measurements at 4 and
8 weeks after surgery, respectively. Osteophytes in the alendronate group were more cartilaginous in
composition [i.e., lower bone mineral density (BMD)] compared to the untreated group. Histological
analysis conﬁrmed the osteophyte inhibitory effect of alendronate, and also veriﬁed reduced degener-
ation of the articular cartilage compared to untreated rats.
Conclusion: Our study conﬁrmed that alendronate administration will reduce osteophyte formation in
a rat model of post-traumatic osteoarthritis, partially through the inhibition of secondary remodeling of
osteophytes. Our study is the ﬁrst to employ elemental Strontium as a tracer of bone turnover in the
pathogenesis of osteoarthritis and to assess the efﬁcacy of bisphosphonate antiresorptive drug inter-
ventions on osteophytogenesis.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Many bone disorders, including Osteoarthritis (OA), are associ-
ated with aberrant bone turnover. For OA, bony osteophyte (OST)
formation and subchondral plate sclerosis are commonly detected
by planar X-ray, and along with joint space narrowing are oftennual Meeting of the Osteoar-
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s Research Society International. Pused as markers for the diagnosis and staging of OA progression1,2.
Bisphosphonate drugs have an afﬁnity for bone mineral, and upon
binding to bone will be taken up by osteoclast cells during bone
resorption, thereby impairing their function. Alendronate (ALN) has
been reported to be effective in reducing OST occurrence in a rat
model of OA3,4, and in human patients5 e an effect that the closely
related Risedronate has not been shown to inﬂuence4,6,7.
Methodology capable of detecting bone turnover is critical for
the diagnosis of metabolic bone disorders and in the study of drug
interventions on disease progression. In this study, we have
employed sub-therapeutic levels of elemental Strontium (Sr) drugs
as molecular probes to detect early sites of bone turnover in the
developing pathogenesis of OA. Sr serves as a surrogate for Calciumublished by Elsevier Ltd. All rights reserved.
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bone. Electron probe microanalysis (EPMA) enables us to detect
elemental Sr deposited in bone8, with greatly improved resolution
compared to current methods of detection (i.e., scintigraphy,
autoradiography9). Under EPMA, Sr is seen to incorporate into
mineralizing crystals by replacing Ca atoms, with deposition
occurring predominantly in areas where new bone is being
formed10. Radioactive isotopes of Sr have been used for either
scintigraphy (invivo)11 or auto-radiographic studies (exvivo) to
diagnose metabolic bone disorders12,13. However, employing the
stable (non-radioactive) isotope of Sr may prove to be just as
effective with suitable detection methods. Sr deposits predomi-
nantly in areas where new bone is undergoing mineralization (e.g.,
regions undergoing intramembranous or endochondral ossiﬁca-
tion), or at remodeling trabecular osteoid seams. Therefore, the
greater the rate of turnover the greater the Sr incorporation,
serving as an excellent tool to potentially study disease pathogen-
esis, progression and response to therapy in OA.
OST development (osteophytogenesis) commences early during
sub-clinical stages of OA pathogenesis, where they initially appear
as cartilaginous outgrowths which later become calciﬁed through
endochondral ossiﬁcation14. Mature OSTs are permanent ectopic
bones which can reduce the patient’s quality of life, by limiting the
movement of the affected joint and serving as a signiﬁcant
predictor of pain and morbidity in OA patients15, although they are
not always directly correlated with the most severe OA pain16,17.
Nonetheless, the reduction of OST development could be a target
for OA treatment, as subsequent surgical interventions and revision
arthroplasty are often complicated by aberrant bony growth and
anatomical malalignment. However, such an approach would
require the early detection of OST development which is an
essential pre-requisite for early intervention with an appropriate
disease-modifying treatment strategy.
Several reports have suggested the utility of bisphosphonate
drug strategies for the treatment of post-traumatic secondary
osteoarthritis (PTOA)3e7,18e21. In the current study, our group
investigated the distribution and incorporation of Sr in newly
mineralizing bone of normal and PTOA rats, with or without ALN
drug treatment. Using elemental Sr as a Ca surrogate, we mapped
potential bony sites of OST formation at very early stages of their
development. Bone volume percentage (%BV) and the bone mineral
density (BMD) of OSTs were measured using in-vivo micro-
computed tomography (CT), and we compared these data with
histological assessment of OST growth and articular cartilage
health.Material and methods
Surgical model of PTOA
A total of 15 6-week-old (w260 g) female Sprague-Dawley rats
were obtained from University of Alberta Biosciences Animal
Services. All procedures concerning animal ethics were carried out
according to the animal care and use committee of the University of
Alberta. OAwas induced surgically byMedial Meniscectomy (MMx)
surgery22. In brief, rats were anesthetized with 2% isoﬂurane in
oxygen, the right knee joint shaved and disinfected, then exposed
using a medial parapatellar incision. The medial collateral ligament
was cut with a scalpel blade, and themedial meniscus was carefully
resected in entirety. Joint tissues were ﬂushed with sterile saline
after the surgery and both the joint capsule and skin sutured using
5-0 absorbable Vicryl suture (Ethicon Inc., CA, USA). A single dose
(0.1 mg/kg) of Meloxicam analgesic (Metacam, Boehringer Ingel-
heim Ltd., CA, USA) was administered subcutaneously to ratsimmediately after the surgery with animals permitted to freely
ambulate in cages during the course of study.
Experimental design
Twelve animals underwent MMx surgery, and were randomly
divided into two groups: ALN-treated MMx group (n¼ 6) and
untreated MMx (n¼ 6). Rats from both groups were euthanized at
two different time-points post-surgery: 4 weeks (n¼ 3) or 8 weeks
(n¼ 3), and compared with an age-matched group of Normal
controls (uninjuredeuntreated, n¼ 3) to contrast differences in
micro-CT, EPMA, and histology results.
Drug dosage
All treatments started the day after surgery and continued until
euthanasia. ALN was injected in rats subcutaneously twice weekly
at the dosage of 0.12 mg/kg of body mass, consistent with the “high
dose” of ALN for OA treatment in rats, as published by Hayami
et al.3. Vehicle (saline) was injected in the untreated group subcu-
taneously twice a week.
All rats were orally gavaged with Sr ranelate (PROTOS, Servier
Laboratories, Australia) using an 18-gauge, 2-inch curved animal
feeding needle (Harvard Apparatus), as the source of readily
bioavailable Sr tracer for the last 10 days prior to euthanization e
based on reports of Sr plasma concentration reaching steady-state
levels after 10 days23. As our intentionwas to employ Sr ranelate as
a tracer of newly mineralizing bone, we employed a daily dosage of
308 mg/kg, a level which is sufﬁcient to show detectable levels in
bone whilst remaining well below the recently reported thera-
peutic dosage for Sr ranelate in rats24, where 900 mg/kg/day was
used to increase bone strength and promote bone forming activity.
Furthermore, as the Sr compound was administered very late in the
8-week experimental design (and for only the last 10 days), we
consider it unlikely that it contributed to the OST formation (or
suppression with ALN) in this study.
In-vivo micro-CT image acquisition
In-vivo micro-CT scans (w35 min) of the right knee joint were
performed temporally: baseline (time zero), mid-point at 4 weeks,
and at the experimental end-point of 8 weeks. Scans at baseline
(1 day after surgery) were performed to record bone parameters at
time zero and to verify the complete surgical removal of the medial
meniscus and adjacent joint structures. Rats were anesthetized
with 2% isoﬂurane in oxygen administered through a nasal cone for
the duration of micro-CT imaging. We employed the Skyscan 1076
in-vivo micro-CT (SkyScan NV, Kontich, Belgium) was utilized for
imaging. X-ray source setting were adjusted at 70 kV, and 139 mA,
with low energy X-rays removed using a 1.0 mm aluminum ﬁlter.
Using a 0.5 rotation step, we acquired 394 two-dimensional (2D)
digital projection views at an exposure time of 1180 ms with an
image resolution of 18 mm. 2D projections were reconstructed
using a modiﬁed Feldkamp back-projection algorithm to obtain
cross-sectional slices of the samples. Reconstruction was
completed with an image to cross-section threshold of
0.0000e0.0600 for all data sets. All analyses were conducted
blinded to the treatment.
Volumetric OST quantitation by micro-CT
We followed the method established by Batiste et al. in rabbits,
for cross-application with rats to measure OST bone volume25. We
further utilized micro-CT to quantify the BMD of OSTs in different
treatment groups, after calibration with vendor supplied
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Analyser software package (version 1.10.0.1) was used to binarize
2D transverse images with a gray scale thresholding of 60/255 to
measure %BV and BMD of OSTs. A single operator identiﬁed and
manually separated OSTs from the adjacent normal cortical bone
within each transverse section (Fig. 1). OSTs were outlined based on
user-deﬁned criteria of location and morphological appearance. All
analyses were conducted blinded to the treatment.Specimen preparation and histological analysis
After euthanization, the right femur from all animals was
dissected free of muscle and soft tissue and ﬁxed in 10% neutral
buffered formalin (Fisher Scientiﬁc, USA). The distal femoral
epiphysis was then sectioned using a transverse plane through the
collateral ligament origins, with a second transverse block being
taken at the metaphysis using a diamond wafer saw (Buehler Ltd.,
Lake Bluff, IL, USA). The ﬁrst block was immersed in decalciﬁcation
solution (Cal-Ex II, Fisher Scientiﬁc, USA) for 2 weeks, and sent for
histological sectioning. The second bone block was immersed in
acetone for 1 week to remove fat. For elemental distributionFig. 1. In-vivo micro-CT based OST segmentation (user-deﬁned demarcation) from reconstru
the course of the experiment. (a) One day after MMx surgery, no OST was detected; (b) Afte
manually segmented (red/blue area), after cross-reference with baseline micro-CT images aanalysis, it is necessary to preserve minerals, thus decalciﬁcation
should be avoided. Subsequently, the undecalciﬁed specimen was
embedded in Epoxy resin and the cut-face was polished with dia-
mond corundum to prepare a very smooth surface for EPMA.
Decalciﬁed blocks were sectioned at 5 mm and stained with
Safranin-O/Fast green to evaluate cartilage health and osteophy-
togenesis. The modiﬁed Mankin scoring system36 was used to
evaluate OA severity in each of the treatment groups, with the two
independent observers being blinded as to the treatment group.
Additional 14 mm sections were stained employing a modiﬁed
Tetrachrome method26, where mature lamellar bone stained red,
whilst woven bone stained blue with red patches. Cartilage
appeared pale blue, whilst calciﬁed cartilage was pink-red in color.
Osteoid, red blood cells and connective tissue stained deep blue,
yellow-orange and pale blue, respectively.Ex-vivo EPMA
Brieﬂy, the second bone block was defatted in acetone for
1 week, then dried in a 40C oven and embedded in epoxy (Epo-
Kwick, Buehler Ltd., Lake Bluff, IL, USA). Cylindrical moulds 1 inchcted coronal image stacks of the distal femoral epiphysis from the same MMx rat over
r 4 weeks OSTs were noted forming on the lateral margins of the bone; (c) OSTs were
nd rendered three-dimensional (3D) image models.
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facing down for ﬁne grinding and polishing (w0.5 mm) on an
automated lapping plate. Sample surfaces were then coated with
20e30 nm thickness Carbon and EPMA undertaken with a Cameca
SX100 electron probe (Cameca, Paris, France), equipped with both
Wavelength Dispersive Spectroscopy (WDS) and Energy Dispersive
Spectroscopy (EDS), using vendor supplied PeakSight 4.1 (Cameca,
Paris, France) analysis software. Elemental Sr distribution was
mapped using EPMA at a resolution of 5 mm with voltage and
current set at 15 kV and 30 nA, respectively. Again, all assessments
were conducted blinded to the treatment.
Statistical analysis
Statistical analysis was conducted using SPSS software package
version 17.0. One-tailed independent t-test was used to compare
sample means of OST volume and BMD. For Mankin scores, theFig. 2. In-vivo micro-CT image rendering of the gross appearance of the osteophytic region
formation at starting point; (b) Osteophytic margin on the femur is highlighted in gray in th
indicating central full-thickness cartilage deterioration on the medial condyle to the right.two-tailed t-test was used. For all comparisons, the signiﬁcance
level was set at P& 0.05. Data in the table and bar graphs are
reported as the mean and 95% conﬁdence interval (CI).
Results
In-vivo micro-CT quantitative analysis
Age-matched normal controls did not show any OST develop-
ment during the 8-week experimental period. In contrast, the
untreated MMx group developed the largest (2.276 mm3) and
densest (0.673 g/cm3) OSTs at 8 weeks post-surgery, located
predominantly at the lateral articular cartilage - synovial margin,
adjacent to the medial collateral ligament origin (Fig. 2). For the
ALN-treated MMx group, OST volume was measured at 1.111 mm3
and BMD at 0.613 g/cm3 (Table I). Thus, compared to the untreated
MMx group, rats treated twice weekly with ALN had signiﬁcantlyin the same MMx untreated rat joint, from baseline to end-point. (a) No ectopic bone
e same animal after 8 weeks; (c) Anterior view of the same rat femur after dissection,
Red arrows indicate osteophytic margin.
Table I
Volumetric measurements of OSTs
Treatment group OST BV% OST BMD Mankin score
(n¼ 3)
ALN group
4 weeks (n¼ 6) 0.998, [0.727,
1.270]*
0.587, [0.551,
0.625]
2.666, [1.23,
4.100]
8 weeks (n¼ 3) 1.111, [0.977,
1.246]y
0.613, [0.508,
0.720]z
5.000, [0.032,
9.968]
OA group
4 weeks (n¼ 6) 1.663, [0.861,
2.464]*
0.611, [0.558,
0.665]
3.333, [1.900,
4.768]
8 weeks (n¼ 3) 2.276, [0.793,
3.760]y
0.673, [0.636,
0.710]z
6.000, [1.697,
10.303]
Values represent the mean with 95% CIs. Matching symbols indicate a signiﬁcance
difference between the groups (P< 0.05).
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volume at 4 and 8 weeks respectively (P< 0.05, Fig. 3). The OST in
ALN group measured reduced BMD than the untreated group at
both time-points, however, that difference was only signiﬁcant
after 8 weeks of treatment (P< 0.05).
Ex-vivo EPMA qualitative analysis
We employed stable, elemental Sr as a molecular tracer of
mineralizing events in an effort to detect osteophytogenesis at an
early, sub-clinical stage of development. In agreement with clas-
sical results from 85Sr autoradiography in children27, EPMA maps
illustrated a uniform deposition of Sr over actively remodeling
trabecular surfaces in our group of normal juvenile rats, high-
lighting newly remodeling bone upon the growing trabecular
surfaces. In contrast, MMx surgery altered periarticular bone
turnover, showing signiﬁcantly reduced deposition of Sr on
trabecular surfaces, with a shift toward increased depositionFig. 3. Micro-CT analysis of highly variable OST bone volume (left) and mineral density
(right) at 4 and 8 weeks after surgery. ALN-treatment resulted in OST prevention, and
surprisingly they possessed lower BMD, compared to ones from PTOA-untreated
group. The bar graphs represent the mean 95% CIs. Matching symbols indicate
signiﬁcant differences between groups (P< 0.05), with the number of independent
observations being six at 4 weeks post-surgically, and 3 at 8 weeks.localized to developing osteophytic margins (Fig. 4). Surprisingly,
ALN-treated rats exhibited less Sr incorporation at sites of OST
formation indicating reduced bone mineralizing events in that
region (i.e., reduced osteophytogenesis). Again, the loss of trabec-
ular bone mass and degeneration of articular cartilage were
dominant characteristics of PTOA rats at the 8 weeks experimental
end-point. In contrast, bone loss in the ALN-treated group was
reduced due to the inhibition of osteoclast-mediated bone
resorption, however, new bone formation was also perturbed.
The growth plates in all groups showed signiﬁcant accumulation
of the Sr tracer due to longitudinal bone growth in these juvenile
rats. Moreover, the distal metaphyseal growth plates from all
bisphosphonate treated rats in this study exhibited signiﬁcantly
increased growth plate width at the primary spongiosum. We also
noted that subchondral bone sclerosis was not observed in this rat
MMx model of PTOA at the 8-week time-point.Safranin-O/fast green and tetrachrome histological analysis
When examining Safranin-O/fast green stained sections from
normal control rats, the articular cartilage was healthy and unre-
markable, showing abundant chondrocytes surrounded by full-
thickness, richly red staining proteoglycan and an uninterrupted
continuous surface. In contrast, sections from the MMx untreated
groups had developed evidence of PTOA, with erosive damage to
the articular cartilage surface and cartilage ﬁbrillation, patchy
proteoglycan staining and the signiﬁcant loss of chondrocytic cells.
Metaplastic cartilaginous outgrowths were evident at the articular
cartilage-synovial joint margins, as was chondrocytic hypertrophy
with evidence of apoptosis and endochondral ossiﬁcation e
resulting in the mineralized ﬁbrocartilage of primary OST. Several
primary OST had been remodeled by osteoclasts into cavernous,
expanding secondary OST of greater mineral density under Tetra-
chrome staining, likely through osteoblastic lamellar bone
formation.
As previously reported, the ALN-treated group exhibited
improved cartilage health compared to the untreated group, in
terms of cartilage continuity, chondrocyte cellularity and proteo-
glycan content. Of great interest was that OST in this group were
smaller and more cartilaginous in composition, as evidenced under
Safranin-O and Tetrachrome staining (Fig. 5). Secondary OST
remodeling was not readily detected in any of the ALN-treated
MMx animals, again suggesting that the bisphosphonate content
trapped in the mineralizing primary OST resisted subsequent
efforts of osteoclast activity and secondary OST formation by
osteoblasts into cavernous (but denser) lamellar bone.Discussion
We propose that ALN inhibits osteophytogenesis in rat models
of PTOA by perturbing the secondary remodeling of primary OST,
thereby inhibiting their erosive expansion and lamellar bone
formation in three dimensions, whilst maintaining an immature
OST phenotype. That postulate is supported by the fact that
signiﬁcantly smaller and less dense OST were measured in ALN-
treated group compared to the untreated group. Furthermore,
OST in ALN-treated rats were measured with reduced Sr tracer
incorporation, suggestive of less mineralizing bone formation
activity e an event that may be linked to osteoclast functional
impairment, as bone formation is tightly coupled to bone resorp-
tion. Histology demonstrated more cartilaginous OST in the ALN-
treated group, as further evidence of impaired mineral formation,
and supporting the reduced BMD measurements in OSTs under
micro-CT.
Fig. 4. EPMA mapping of elemental Sr incorporation in the distal femoral epiphysis of the rat, sectioned in the transverse plane through the collateral ligament origins. Image ﬁeld
of view represents the entire medial femoral condyle in cross-section, with the articular cartilage surface to the top, and yellow arrowheads indicating the same metaphyseal
growth plate sectioned in two planes. Lighter bright-blue colors indicate the incorporation of Sr into actively mineralizing regions of cortical and trabecular bone. (a) Normal control
bone with active trabecular remodeling and new bone mineralization at the primary spongiosum of the growth plate; (b) Untreated rat bone 4 weeks after MMx. Note the shift of Sr
incorporation toward the osteophytic margins (red arrows); (c) OST inhibition in the ALN-treated group 4 weeks after MMx. Image Scale bars (bottom left) represent 1000 mm.
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the preservation of subchondral bone from sclerosis has been
suggested to be beneﬁcial in retarding OA progression28. Therefore,
a potential role for bisphosphonate therapy in OA was suggested20.
However, unremarkable outcomes of bisphosphonate use in clinical
trials of OA treatment has made it difﬁcult to accept or refute them
as an entire class of disease-modifying OA drugs7,29. Conversely, in
animal models, ALN has been shown to preserve subchondral bone
health along with prevention of OST incidence and inhibition of
vascular invasion into calciﬁed cartilage in rat models of PTOA3,4,
and reduce spinal OSTs and disc space narrowing in human
patients5, suggesting an indication for the use of ALN in the
preventative treatment of OA. Our ﬁndings in this study conﬁrmed
those beneﬁcial effects of ALN on reducing OST incidence and
preserving cartilage health in the rat model of PTOA.
However, our study does not answer why certain BP candidates
including ALN or Etidronate inhibit OST formation to some extent,
whereas others such as Risedronate have not been shown to
inﬂuence OST formation. Hayami et al. showed that ALN-treatment
reduced the local release of transforming growth factor b (TGF-b) in
the osteoarthritic joint in an animal model of OA, and suggested
that was a possible mechanism of OST inhibition3. However,
Risedronate has also been shown to reduce TGF-b in ovariecto-
mized mice30, but shows no effect on OST inhibition in rat models
of PTOA. Other growth factors, including vascular endothelial
growth factor (VEGF) and basic ﬁbroblast growth factor (bFGF), may
be involved in OST formation by stimulating angiogenesis and bone
matrix formation. ALN administration was reported to down-
regulate the expression of both VEGF and bFGF in rats with
gastric ulcers31, however, the complete picture of ALN inhibition of
OST formation remains to be determined in entirety.
The Sr tracer results indicated that growth plates in the ALN-
treated group were not being remodeled into trabecular bone atthe primary spongiosum as witnessed for the PTOA and normal
groups, indicating the inhibition of osteoclast-mediated bone
resorptive events. That was presumably as the bisphosphonate
content trapped in those rapidly mineralizing centers resisted
subsequent efforts of osteoclast activity and trabecular bone
modeling. Consequently, wider growth plate in this treatment
group was observed. That observation of signiﬁcantly increased
growth plate width in the juvenile rat after bisphosphonate treat-
ment was also noted for the closely related drug Risedronate in
a recently published micro-CT study from our laboratory4.
This study is the ﬁrst to employ elemental Sr as tracer of bone
turnover in the pathogenesis of OA. Sr drugsmay ﬁnd utility as non-
ionizingdiagnostic tracers of bonediseases and to assess the efﬁcacy
of drug intervention in OA. When taken in sufﬁciently high
concentration, Sr ranelate has been proven to signiﬁcantly reduce
the risk of fracture in postmenopausal women in several multi-
centre clinical trials32,33. However, the use of sub-therapeutic levels
of Sr compounds as molecular tracers in the diagnosis of bone
disorders such as OA has not been employed to date, and might
prove as valuable as its therapeutic role in osteoporosis. It has been
suggested that Sr contributes to bone mineralization by ionic
exchange at hydroxyapatite crystal surface, and/or by heteroionic
substitution of Ca atoms by Sr34,35. Li et al. performed small-angle X-
ray scattering, X-ray diffraction, and X-ray ﬂorescence analysis to
characterize Sr distribution within mineral crystal of bone and
showed that 0.5 out of 10 Ca atoms in the hydroxyapatite crystal can
be replaced bySr10. However, other thanby substitution, Sr ismostly
uptaken by newly mineralizing ﬁbrocartilaginous and or bony
precursor connective tissues, such as osteoid. Thus, it is clear that the
extent of Sr incorporation intomineralizing bonewill be dictated by
a greater number of factors including the type of mineralizing bone
(trabecular, cortical, OST), the Sr drug dosage, duration of treatment,
and degree of mineralization in existing bone to name a few.
Fig. 5. Histological evaluation of OSTs at the distal epiphysis of the medial femoral condyle. (a) Normal control tissue, Tetrachrome, 10; (b) ALN-treated MMx at 4 weeks, Tet-
rachrome, 10; (c) Untreated MMx at 4 weeks, Tetrachrome, 10; (d) ALN-treated MMx at 8 weeks, Safranin-O/fast green, 10: note chondrocytes undergoing hypertrophy and
apoptosis (white arrow), followed by cartilage mineralization and bony tissue formation (black arrow); (e) Untreated MMx at 8 weeks, Safranin-O/fast green, 10: note metaplastic
cartilaginous outgrowths forming bone through endochondral ossiﬁcation, fused with original lamellar bone (dashed line), covered by articular cartilage (white arrows); (f) ALN-
treated MMx at 8 weeks, Tetrachrome, 10: note OST maturation is retarded by ALN intervention remaining cartilaginous in composition, compared to untreated MMx (g); (h) ALN-
treated MMx at 8 weeks, Tetrachrome, 20: osteophytic zone attracting neovascularization with yellow staining erythrocytes in blood vessel lumen (white arrow); (1) Untreated
MMx at 8 weeks, Tetrachrome, 40: cavernous expansion of primary OSTs creating bone marrow space, with secondary remodeling of OSTs by active cuboidal osteoblasts (white
arrows), depositing blue stained osteoid on remnants of calciﬁed cartilage (white arrowheads).
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treatment group remained small, due to the complexity and
expense of coordinating precise regional analyses of drug-dosed
bone regions between the micro-CT, EPMA and histological evalu-
ations that were employed. However, as our study purpose was to
establish the utility of Sr compounds as molecular tracers of bone
turnover, our ﬁndings should remain of signiﬁcant interest for
others looking to employ novel methodology for mapping bone
turnover, other than traditional, histology-based undecalciﬁed
Calcein labeling. Another study limitation was that Sr mainly
incorporated into mineralizing bone and ﬁbrocartilage forming
during the 10-day dosing period. Therefore, wewere only detecting
OST in the process of endochondral ossiﬁcation, or being remod-
eled during the last 10 days of the 8 week experimental period, as
only those mineralizing sites would readily incorporate Sr ions.
However, that “speciﬁcity” of Sr incorporation into newly miner-
alizing tissues, as evidenced by more advanced imaging modalities
may in the future be of enormous value to investigate the rate of
bone turnover in the clinic.
Thus, in conclusion, our results support the indication of ALN in
the prevention of OST formation, which if administered immedi-
ately after traumatic injury (over a yet to be deﬁned therapeutic
window), may prove an effective disease-modifying drug treat-
ment to slow the progression of secondary OA.
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